Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity

C Brugnara1, D Zelmanovic, M Sorette

  • 1Department of Pathology, The Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

American Journal of Clinical Pathology
|August 1, 1997
PubMed
Summary

This study introduces reticulocyte hemoglobin (retHb) as a novel measure of red blood cell production. RetHb and the red blood cell hemoglobin to reticulocyte hemoglobin ratio (rbcHb/retHb) can assess red blood cell survival and monitor anemia therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated cell counts on CSF samples: A multicenter performance evaluation of the GloCyte system.

International journal of laboratory hematology·2017
Same author

Clinical Applications of Automated Reticulocyte Indices.

Hematology (Amsterdam, Netherlands)·2016
Same author

Nitrosylation of Sickle Cell Hemoglobin by Hydroxyurea.

The Journal of organic chemistry·2015
Same author

Drugs for preventing red blood cell dehydration in people with sickle cell disease.

The Cochrane database of systematic reviews·2007
Same author

Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states.

Clinical and laboratory haematology·2006
Same author

Development and standardization of multiplexed antibody microarrays for use in quantitative proteomics.

Proteome science·2004

Area of Science:

  • Hematology
  • Clinical Chemistry
  • Red Blood Cell Metabolism

Background:

  • Traditional reticulocyte counts offer limited insight into bone marrow activity.
  • Existing methods do not fully capture reticulocyte hemoglobin content or cellular variations.
  • A more comprehensive parameter is needed to assess erythropoiesis and red blood cell health.

Purpose of the Study:

  • To introduce and evaluate reticulocyte hemoglobin (retHb) as an integrated parameter for erythropoietic activity.
  • To assess the utility of retHb and the rbcHb/retHb ratio in evaluating red blood cell survival and hemolytic anemias.
  • To explore the application of retHb in monitoring therapeutic responses in various anemias.

Main Methods:

  • Defined reticulocyte hemoglobin (retHb) as the product of absolute reticulocyte count and reticulocyte cell hemoglobin content.

Related Experiment Videos

  • Calculated red blood cell hemoglobin (rbcHb) by subtracting retHb from total hemoglobin.
  • Determined the rbcHb/retHb ratio as an indicator of red blood cell survival.
  • Analyzed retHb and rbcHb/retHb in normal subjects and patients with sickle cell diseases (SS and SC) and those undergoing specific therapies.

    • Main Results:

    • Established normal retHb values in healthy subjects (1.76 +/- 0.59 g/L).
    • Observed lower retHb in SC disease compared to SS disease, with variations based on alpha-globin gene status.
    • Demonstrated altered rbcHb/retHb ratios in sickle cell diseases, suggesting reduced red blood cell survival.
    • Showcased the potential of retHb to reflect changes in patients receiving hydroxyurea, iron, or r-HuEPO therapy.

    Conclusions:

    • Reticulocyte hemoglobin (retHb) provides a quantitative measure of hemoglobin within the circulating reticulocyte compartment.
    • The retHb parameter and the rbcHb/retHb ratio offer insights into red blood cell survival and hemolysis severity.
    • These novel parameters can enhance the monitoring of anemia treatments, including hydroxyurea, iron, and r-HuEPO therapies.